Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebacin for persistent high-risk HPV infection in cervical and vaginal intraepithelial neoplasia
ChiCTR2200057878Phase 4Recruiting
- Sponsor
- The Second Hospital of Jilin University
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of rebacin in cervical intraepithelial neoplasia (CIN), vaginal intraepithelial neoplasia (VAIN) and human papillomavirus infection (2 arms), sponsored by The Second Hospital of Jilin University. Primary endpoints: HPV status and Cytological testing. Started May 2022; status: recruiting.
02
Drugs
rebacin
03
Conditions
cervical intraepithelial neoplasia (CIN)vaginal intraepithelial neoplasia (VAIN)human papillomavirus infection
Beyond the preview
Go deeper on ChiCTR2200057878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057878.